3,845 Shares in Solventum Co. (NYSE:SOLV) Purchased by Kennondale Capital Management LLC

Kennondale Capital Management LLC purchased a new position in shares of Solventum Co. (NYSE:SOLV) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,845 shares of the company’s stock, valued at approximately $254,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Modus Advisors LLC acquired a new stake in Solventum during the fourth quarter worth about $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum in the fourth quarter valued at about $26,000. True Wealth Design LLC grew its stake in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares in the last quarter. Crews Bank & Trust acquired a new stake in shares of Solventum in the fourth quarter valued at about $32,000. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Solventum in the third quarter valued at about $35,000.

Solventum Trading Up 1.2 %

NYSE:SOLV opened at $75.04 on Tuesday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business’s 50 day moving average is $74.65 and its two-hundred day moving average is $71.30. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a market cap of $12.98 billion and a PE ratio of 27.29.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SOLV. Mizuho increased their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Morgan Stanley increased their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group increased their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.